{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:56:14Z","timestamp":1787579774264,"version":"build-2736575974"},"reference-count":65,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,7,3]],"date-time":"2007-07-03T00:00:00Z","timestamp":1183420800000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Drug Reviews"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Guidelines recommend that dual antiplatelet therapy using aspirin and clopidogrel should be administered to the majority of patients with acute coronary syndromes, including those undergoing percutaneous coronary intervention (PCI). However, the results of a large randomized, placebo\u2010controlled study suggest that a 300\u2010mg loading dose of clopidogrel must be administered at least 15 h prior to PCI in order to achieve a significant reduction in peri\u2010PCI thrombotic events. Other data suggest that 2 h of pretreatment may be sufficient if a 600\u2010mg loading dose is used. Since it is often difficult to achieve an adequate pretreatment goal with clopidogrel in clinical practice, more rapid achievement of platelet P2Y<jats:sub>12<\/jats:sub> inhibition may improve patient outcomes. Prasugrel, [6\u2010[2\u2010(3,4\u2010diflurophenyl) cyclopropyl1\u20101\u2010y1] amino\u20102\u2010propylthio\u20109?\u2010D\u2010ribofuranosyl\u20109H\u2010purine (AZD6140), and cangrelor are platelet P2Y<jats:sub>12<\/jats:sub> receptor antagonists currently in development that offer faster acting inhibition of adenosine diphosphate (ADP)\u2014induced platelet aggregation. These agents act upon the same platelet receptor as clopidogrel, but are distinguished by their routes of administration, reversibility, and pharmacodynamic properties. Prasugrel is an orally administered agent that provides faster, higher, and more consistent inhibition of platelet aggregation than clopidogrel. The results of Phase II testing suggest that the risk of bleeding is similar in prasugrel\u2010 and clopidogrel\u2010treated patients. AZD6140 is another orally administered platelet inhibitor with rapid and reversible action. Again, Phase II testing suggests similar bleeding risk for clopidogrel. Preliminary evidence suggests that clinical outcomes may be better in prasugrel\u2010 and AZD6140\u2010treated patients than in clopidogrel\u2010treated patients. Cangrelor is an intravenously administered, reversible, short\u2010acting agent with a rapid onset of activity. Bleeding risk and clinical outcomes data are similar in cangrelor\u2010 and abciximab\u2010treated patients. The results of ongoing Phase III clinical trials involving more than 40,000 patients will demonstrate whether these agents fulfill their potential to improve outcomes in PCI\u2010treated patients by providing faster, higher, and more consistent inhibition of platelet aggregation.<\/jats:p>","DOI":"10.1111\/j.1527-3466.2007.00013.x","type":"journal-article","created":{"date-parts":[[2007,7,3]],"date-time":"2007-07-03T14:18:32Z","timestamp":1183472312000},"page":"188-203","source":"Crossref","is-referenced-by-count":23,"title":["Optimizing Platelet P2Y<sub>12<\/sub> Inhibition for Patients Undergoing PCI"],"prefix":"10.1111","volume":"25","author":[{"given":"Steven","family":"Steinhubl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,7,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.07.036"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.014"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537100600565551"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.536276"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.17.2096"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.10.010"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02336-7"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.24.2823"},{"key":"e_1_2_5_11_1","first-page":"199A","article-title":"Clinical outcomes wtih AZD6140, an oral reversible ADP receptor antagonist, compared wtih clopidogrel in patients with acute coronary syndromes","volume":"47","author":"Cannon C","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2006.01.013"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67660-X"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_5_15_1","first-page":"212A","article-title":"Can greater inhibition of platelet aggregation be tolerated? Evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS)","volume":"47","author":"Emanuelsson H","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.11.014"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072771.11429.83"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000157138.02645.11"},{"key":"e_1_2_5_19_1","article-title":"Clopidogrel resistance?","author":"Gurbel PA","year":"2006","journal-title":"Thromb Res"},{"key":"e_1_2_5_20_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1160\/TH05-03-0208","article-title":"Stereoselective inhibition of human platelet aggregation by R\u2010138727, the active metabolite of CS\u2010747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor","volume":"94","author":"Hasegawa M","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.10.2316"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615238"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000160869.75810.98"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01954-X"},{"key":"e_1_2_5_25_1","unstructured":"HustedS EmanuelssonH HeptinstallS ClarkS PetersG(2005)Greater and less variable inhibition of platelet aggregation (IPA) with AZD6140 the first oral reversible ADP receptor antagonist compared with clopidogrel in patients with atherosclerosis (The DISPERSE Study).Paper presented atEuropean Society of Cardiology ; Stockholm ."},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi754"},{"key":"e_1_2_5_27_1","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS\u20102","volume":"2","author":"ISIS\u20102 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"e_1_2_5_28_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.fjc.0000210069.47205.c0","article-title":"The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects","volume":"47","author":"Jakubowski J","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_5_29_1","article-title":"A multiple dose study of prasugrel (CS\u2010747), a novel thienopyridine P2Y(12) inhibitor, compared with clopidogrel in healthy humans","author":"Jakubowski JA","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi877"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.08.060"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.01.044"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537100600565510"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.04.029"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.18.2027"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.04.090"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00817-2"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.85.1.92"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.643171"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000161383.06692.D4"},{"key":"e_1_2_5_43_1","unstructured":"PayneCD WintersKJ(2006)A prasugrel 60 mg loading dose achieves faster onset and higher levels of platelet inhibition compared with 300 mg and 600 mg clopidogrel loading doses.Paper presented atTranscatheter Cardiovascular Therapeutics ; Washington D.C."},{"key":"e_1_2_5_44_1","unstructured":"Physicians' Desk Reference.60th edition 2006.Thomson PDR Montvale NJ USA . pp.940\u2010943."},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.03.054"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.007989"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.10.1224"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.11.3194"},{"issue":"2","key":"e_1_2_5_49_1","first-page":"15","article-title":"Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects","volume":"25","author":"Savcic M","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_5_50_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0038-1648859","article-title":"The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450\u20101A","volume":"72","author":"Savi P","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614133"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.047696"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.09.067"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.119372"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi138"},{"key":"e_1_2_5_56_1","first-page":"e166","article-title":"ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)","volume":"113","author":"Smith SJ","year":"2006","journal-title":"Circulation"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.047"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_2_5_59_1","unstructured":"StoreyR HarringtonR HustedS HeptinstallS WilcoxR(2006b)AZD6140 yields additional suppression of platelet aggregation in patients with acute coronary syndromes previously treated with clopidogrel.Paper presented atAmerican College of Cardiology ; Atlanta GA ."},{"key":"e_1_2_5_60_1","unstructured":"StoreyR HustedS(2006a)AZD6140 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronary syndromes without previous clopidogrel treatment.Paper presented atAmerican College of Cardiology ; Atlanta GA ."},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615596"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-02-0105"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.568139"},{"key":"e_1_2_5_64_1","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","article-title":"Absorption, metabolization, and antiplatelet effects of 300\u2010, 600\u2010, and 900\u2010mg loading doses of clopidogrel: Results of the ISAR\u2010CHOICE (Intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) Trial","volume":"112","author":"Von Beckerath N","year":"2005","journal-title":"Circulation"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.502815"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.10.064"}],"container-title":["Cardiovascular Drug Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-3466.2007.00013.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-3466.2007.00013.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T05:55:12Z","timestamp":1697090112000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-3466.2007.00013.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1111\/j.1527-3466.2007.00013.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-3466.2007.00013.x","archive":["Portico"],"relation":{},"ISSN":["0897-5957","1527-3466"],"issn-type":[{"value":"0897-5957","type":"print"},{"value":"1527-3466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}